Test azacitidine with vitamin C to improve DNA changes
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This Phase 2 study tests whether combining azacitidine (a standard blood cancer medicine) with vitamin C helps improve disease control by changing DNA activity in high-risk blood cancers. It may be an option if you have certain types of higher-risk MDS, CMML, or low-blast AML and can meet safety requirements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have one of these diagnoses: higher-risk MDS, CMML (10–29% marrow blasts), or low-blast AML (20–30% marrow blasts)
- Your MDS risk category must be intermediate to very high by IPSS-R (score above 3)
- You have not had treatment with “hypomethylating agents” before (the type like azacitidine or similar medicines)
- You can have azacitidine now and you are not planning azacitidine after a stem cell transplant
- You are not able to get an allogeneic (donor) stem cell transplant, or your care team says you are not eligible
- You can follow the study rules, including stopping vitamin C supplements at least 3 days (preferably longer) before starting and baseline tests
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding high-dose vitamin C (ascorbate) to the standard two-drug treatment (azacitidine and venetoclax) for people with newly diagnosed acute myeloid leukemia who are not candidates for intensive chemo. The goal is to see if the vitamin C makes the standard treatment work better and helps control the leukemia.
This early-phase study tests whether combining two “epigenetic” medicines—azacitidine and decitabine—can improve outcomes for certain bone marrow cancers. It may help if you have a type of myelodysplastic syndrome (MDS) or MDS/MPN overlap that is expected to be sensitive to these medicines.
This study tests whether a pill form of azacitidine (ASTX030) helps people with myelodysplastic syndromes (MDS), CMML, or AML. Some groups may also receive venetoclax; the goal is better blood cancer control for people who aren’t good candidates for intensive chemotherapy.
This trial tests whether adding donated cord blood stem cells to azacitidine can improve outcomes for people with advanced MDS, CMML-2, or a certain type of AML. It may help by giving the treatment a stronger chance to control abnormal blood-forming cells.
This trial tests whether combining azacitidine with enasidenib helps people with myelodysplastic syndrome (MDS) that has an IDH2 mutation. It’s designed for people who are either new to “hypomethylating” treatment or whose MDS returned/worsened after it.
This trial tests whether adding high-dose vitamin C (ascorbic acid) to standard chemotherapy helps treat lymphomas that have come back or not responded, as well as two related blood disorders (CCUS and CMML). The goal is to see if the vitamin C makes the chemo work better.
Hear when a new Myelodysplastic Syndromes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.